Ocular Historical Financial Ratios

OCUL Stock

USD 7.83 0.16 2.09%

Ocular Therapeutix is promptly reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 286 will help investors to properly organize and evaluate Ocular Therapeutix financial condition quickly.

Quick Ratio Current Ratio

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.

About Ocular Financial Ratios Analysis

Ocular TherapeutixFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Ocular Therapeutix investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Ocular financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Ocular Therapeutix history.

Ocular Therapeutix Financial Ratios Chart

At this time, Ocular Therapeutix's Days Of Inventory On Hand is quite stable compared to the past year. Payables Turnover is expected to rise to 2.19 this year, although the value of Free Cash Flow Yield will most likely fall to (0.11).

Price To Sales Ratio Days Sales Outstanding Ev To Sales Inventory Turnover

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Ocular Therapeutix stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Ocular Therapeutix sales, a figure that is much harder to manipulate than other Ocular Therapeutix multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Most ratios from Ocular Therapeutix's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Ocular Therapeutix current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.At this time, Ocular Therapeutix's Days Of Inventory On Hand is quite stable compared to the past year. Payables Turnover is expected to rise to 2.19 this year, although the value of Free Cash Flow Yield will most likely fall to (0.11).

	2022	2023	2024	2025 (projected)
Payables Turnover	0.89	1.2	1.35	2.19
Days Of Inventory On Hand	158.7	159.31	197.23	202.66

Payables Turnover Days Of Inventory On Hand

Ocular Therapeutix fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		-0.05	0.99	-0.77	-0.33	-0.83	-0.32	-0.05	1.0	-0.82	0.08	-0.63	-0.81	0.74	-0.15	0.99	0.81	0.32	-0.67	0.33	0.31	1.0	-0.12	-0.05	0.38	0.21
Ptb Ratio	-0.05		-0.07	0.1	0.55	0.16	0.1	1.0	-0.05	0.16	0.6	0.02	0.09	0.01	-0.02	-0.05	0.12	-0.44	0.0	-0.11	-0.44	-0.03	0.08	-0.97	-0.4	-0.19
Days Sales Outstanding	0.99	-0.07		-0.75	-0.28	-0.79	-0.4	-0.07	0.98	-0.77	0.11	-0.62	-0.77	0.71	-0.17	0.97	0.78	0.25	-0.56	0.4	0.24	0.98	-0.1	-0.01	0.33	0.17
Book Value Per Share	-0.77	0.1	-0.75		0.48	0.93	0.35	0.1	-0.78	0.93	0.09	0.65	0.86	-0.76	-0.49	-0.76	-0.69	-0.42	0.62	-0.32	-0.41	-0.72	0.1	0.0	-0.49	-0.23
Free Cash Flow Yield	-0.33	0.55	-0.28	0.48		0.49	-0.28	0.55	-0.32	0.51	0.82	0.06	0.38	-0.14	-0.13	-0.4	0.02	-0.81	0.55	0.35	-0.81	-0.33	0.21	-0.41	-0.8	-0.41
Operating Cash Flow Per Share	-0.83	0.16	-0.79	0.93	0.49		0.19	0.16	-0.86	1.0	0.12	0.7	0.95	-0.86	-0.36	-0.83	-0.82	-0.44	0.78	-0.22	-0.43	-0.8	0.19	-0.04	-0.48	-0.3
Capex To Depreciation	-0.32	0.1	-0.4	0.35	-0.28	0.19		0.1	-0.31	0.15	-0.38	0.45	0.19	-0.31	-0.12	-0.22	-0.29	0.24	-0.14	-0.97	0.26	-0.26	-0.18	-0.16	0.17	0.2
Pb Ratio	-0.05	1.0	-0.07	0.1	0.55	0.16	0.1		-0.05	0.16	0.6	0.02	0.09	0.01	-0.02	-0.05	0.12	-0.44	0.0	-0.11	-0.44	-0.03	0.08	-0.97	-0.4	-0.19
Ev To Sales	1.0	-0.05	0.98	-0.78	-0.32	-0.86	-0.31	-0.05		-0.85	0.08	-0.65	-0.83	0.77	-0.11	0.99	0.83	0.31	-0.69	0.33	0.3	0.99	-0.14	-0.05	0.37	0.22
Free Cash Flow Per Share	-0.82	0.16	-0.77	0.93	0.51	1.0	0.15	0.16	-0.85		0.14	0.69	0.95	-0.86	-0.36	-0.83	-0.81	-0.45	0.79	-0.18	-0.44	-0.8	0.2	-0.03	-0.49	-0.31
Roic	0.08	0.6	0.11	0.09	0.82	0.12	-0.38	0.6	0.08	0.14		-0.34	0.02	0.22	-0.07	-0.01	0.38	-0.59	0.32	0.41	-0.59	0.06	-0.08	-0.53	-0.55	-0.08
Inventory Turnover	-0.63	0.02	-0.62	0.65	0.06	0.7	0.45	0.02	-0.65	0.69	-0.34		0.76	-0.91	-0.28	-0.57	-0.8	0.01	0.38	-0.45	0.01	-0.6	0.36	0.02	-0.04	-0.34
Net Income Per Share	-0.81	0.09	-0.77	0.86	0.38	0.95	0.19	0.09	-0.83	0.95	0.02	0.76		-0.87	-0.29	-0.81	-0.85	-0.2	0.74	-0.23	-0.2	-0.79	0.38	0.0	-0.24	-0.44
Days Of Inventory On Hand	0.74	0.01	0.71	-0.76	-0.14	-0.86	-0.31	0.01	0.77	-0.86	0.22	-0.91	-0.87		0.32	0.71	0.92	0.12	-0.58	0.35	0.12	0.72	-0.23	-0.09	0.17	0.25
Payables Turnover	-0.15	-0.02	-0.17	-0.49	-0.13	-0.36	-0.12	-0.02	-0.11	-0.36	-0.07	-0.28	-0.29	0.32		-0.17	0.14	0.13	-0.07	0.11	0.12	-0.22	-0.03	-0.02	0.15	0.07
Capex To Revenue	0.99	-0.05	0.97	-0.76	-0.4	-0.83	-0.22	-0.05	0.99	-0.83	-0.01	-0.57	-0.81	0.71	-0.17		0.77	0.36	-0.71	0.23	0.35	0.99	-0.14	-0.06	0.42	0.23
Cash Per Share	0.81	0.12	0.78	-0.69	0.02	-0.82	-0.29	0.12	0.83	-0.81	0.38	-0.8	-0.85	0.92	0.14	0.77		0.02	-0.58	0.37	0.01	0.8	-0.18	-0.19	0.07	0.18
Pocfratio	0.32	-0.44	0.25	-0.42	-0.81	-0.44	0.24	-0.44	0.31	-0.45	-0.59	0.01	-0.2	0.12	0.13	0.36	0.02		-0.51	-0.26	1.0	0.32	-0.02	0.25	0.99	0.24
Interest Coverage	-0.67	0.0	-0.56	0.62	0.55	0.78	-0.14	0.0	-0.69	0.79	0.32	0.38	0.74	-0.58	-0.07	-0.71	-0.58	-0.51		0.09	-0.51	-0.69	0.24	0.16	-0.52	-0.35
Capex To Operating Cash Flow	0.33	-0.11	0.4	-0.32	0.35	-0.22	-0.97	-0.11	0.33	-0.18	0.41	-0.45	-0.23	0.35	0.11	0.23	0.37	-0.26	0.09		-0.28	0.28	0.17	0.17	-0.21	-0.21
Pfcf Ratio	0.31	-0.44	0.24	-0.41	-0.81	-0.43	0.26	-0.44	0.3	-0.44	-0.59	0.01	-0.2	0.12	0.12	0.35	0.01	1.0	-0.51	-0.28		0.31	-0.03	0.24	0.99	0.24
Days Payables Outstanding	1.0	-0.03	0.98	-0.72	-0.33	-0.8	-0.26	-0.03	0.99	-0.8	0.06	-0.6	-0.79	0.72	-0.22	0.99	0.8	0.32	-0.69	0.28	0.31		-0.13	-0.06	0.37	0.21
Income Quality	-0.12	0.08	-0.1	0.1	0.21	0.19	-0.18	0.08	-0.14	0.2	-0.08	0.36	0.38	-0.23	-0.03	-0.14	-0.18	-0.02	0.24	0.17	-0.03	-0.13		-0.03	-0.01	-0.97
Roe	-0.05	-0.97	-0.01	0.0	-0.41	-0.04	-0.16	-0.97	-0.05	-0.03	-0.53	0.02	0.0	-0.09	-0.02	-0.06	-0.19	0.25	0.16	0.17	0.24	-0.06	-0.03		0.2	0.1
Ev To Operating Cash Flow	0.38	-0.4	0.33	-0.49	-0.8	-0.48	0.17	-0.4	0.37	-0.49	-0.55	-0.04	-0.24	0.17	0.15	0.42	0.07	0.99	-0.52	-0.21	0.99	0.37	-0.01	0.2		0.23
Pe Ratio	0.21	-0.19	0.17	-0.23	-0.41	-0.3	0.2	-0.19	0.22	-0.31	-0.08	-0.34	-0.44	0.25	0.07	0.23	0.18	0.24	-0.35	-0.21	0.24	0.21	-0.97	0.1	0.23

Click cells to compare fundamentals

Ocular Therapeutix Account Relationship Matchups

Ocular Therapeutix fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	72.26	12.23	4.2	6.09	21.21	20.15
Ptb Ratio	16.53	6.05	6.11	3.91	4.29	4.5
Days Sales Outstanding	256.97	177.25	151.16	163.5	185.52	286.08
Book Value Per Share	1.25	1.15	0.46	1.14	1.99	2.09
Free Cash Flow Yield	(0.0433)	(0.13)	(0.29)	(0.21)	(0.1)	(0.11)
Operating Cash Flow Per Share	(1.71)	(0.88)	(0.86)	(0.78)	(0.85)	(0.89)
Stock Based Compensation To Revenue	0.43	0.34	0.33	0.3	0.52	0.49
Capex To Depreciation	0.3	0.49	1.76	2.04	0.34	0.32
Pb Ratio	16.53	6.05	6.11	3.91	4.29	4.5
Ev To Sales	62.52	9.82	3.46	4.17	16.25	15.43
Free Cash Flow Per Share	(1.76)	(0.9)	(0.87)	(0.82)	(0.96)	(0.86)
Roic	(0.26)	(0.71)	(0.58)	(0.38)	(0.41)	(0.43)
Inventory Turnover	1.73	3.52	2.3	2.29	1.85	2.71
Net Income Per Share	(2.63)	(0.14)	(0.83)	(1.01)	(1.22)	(1.28)
Days Of Inventory On Hand	210.45	103.55	158.7	159.31	197.23	202.66
Payables Turnover	0.77	0.96	0.89	1.2	1.35	2.19
Sales General And Administrative To Revenue	1.31	0.73	0.63	0.58	0.95	0.9
Research And Ddevelopement To Revenue	9.72	1.65	1.15	1.04	2.0	1.9
Capex To Revenue	0.0483	0.0274	0.0721	0.1	0.0202	0.0192
Cash Per Share	3.75	2.15	1.33	2.45	2.48	3.76
Pocfratio	(23.48)	(8.12)	(3.62)	(5.07)	(10.04)	(10.54)
Interest Coverage	(9.29)	(11.7)	(11.2)	(7.27)	(12.65)	(13.28)
Capex To Operating Cash Flow	(0.0157)	(0.0182)	(0.0623)	(0.0867)	(0.009564)	(0.01)
Pfcf Ratio	(23.12)	(7.98)	(3.41)	(4.66)	(9.94)	(10.44)
Days Payables Outstanding	474.69	380.41	411.87	303.35	270.93	257.38
Income Quality	0.34	10.0	0.84	0.87	0.7	1.19
Roe	(2.1)	(0.12)	(1.79)	(0.89)	(0.61)	(0.58)
Ev To Operating Cash Flow	(20.32)	(6.52)	(2.99)	(3.47)	(7.69)	(8.07)
Pe Ratio	(7.88)	(49.28)	(3.41)	(4.41)	(6.98)	(7.33)
Ev To Free Cash Flow	(20.0)	(6.4)	(2.81)	(3.19)	(7.61)	(7.99)
Earnings Yield	(0.13)	(0.0203)	(0.29)	(0.23)	(0.14)	(0.15)
Net Debt To E B I T D A	1.16	1.39	0.61	1.69	1.8	1.89
Current Ratio	9.23	7.26	4.13	6.66	10.66	8.97
Tangible Book Value Per Share	1.25	1.15	0.46	1.14	1.99	2.09
Receivables Turnover	1.42	2.06	2.41	2.23	1.97	1.87
Shareholders Equity Per Share	1.25	1.15	0.46	1.14	1.99	2.09
Debt To Equity	(16.35)	0.77	0.67	1.82	0.92	0.24
Capex Per Share	0.0138	0.0156	0.0483	0.0763	0.008138	0.007731
Graham Net Net	(0.56)	0.86	0.83	0.0699	0.7	1.74

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Ocular Therapeutix is a strong investment it is important to analyze Ocular Therapeutix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ocular Therapeutix's future performance. For an informed investment choice regarding Ocular Stock, refer to the following important reports:

How To Invest In Ocular

Details

Is Ocular Stock a good investment?

Details

What is Ocular Therapeutix's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.

You can also try the Stocks Directory module to find actively traded stocks across global markets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.22)

Revenue Per Share

0.403

Quarterly Revenue Growth

0.154

Return On Assets

(0.31)

Return On Equity

(0.95)

The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Ocular Historical Financial Ratios

About Ocular Financial Ratios Analysis

Ocular Therapeutix Financial Ratios Chart

Price To Sales Ratio

Ev To Sales

Inventory Turnover

Ocular Therapeutix fundamentals Correlations

Ocular Therapeutix Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ocular Therapeutix fundamentals Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Days Payables Outstanding	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Days Sales Outstanding	+ 0.99	Price To Sales Ratio

Pe Ratio	- 0.97	Income Quality
Roe	- 0.97	Pb Ratio
Capex To Operating Cash Flow	- 0.97	Capex To Depreciation
Roe	- 0.97	Ptb Ratio
Days Of Inventory On Hand	- 0.91	Inventory Turnover
Days Of Inventory On Hand	- 0.87	Net Income Per Share